TITLE

The skinny on errors with obesity drug names

PUB. DATE
May 2015
SOURCE
Pharmacy Today;May2015, Vol. 21 Issue 5, p88
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information on medications related to or used in the treatment of obesity. Topics discussed include potential confusion between the trade names Xeloda, an anticancer medication, and Xenical, an antiobesity drug, rules created by a hospital unto its computer system to alert pharmacists about the need for dosing adjustments based on patients' estimated creatinine clearance, and reports regarding the use of metoprolol instead of topiramate for weight loss.
ACCESSION #
102485167

 

Related Articles

  • Obesity Drug Inhibits Prostate Tumor Growth.  // Ascribe Newswire: Medicine;3/22/2004, p41 

    The Burnham Institute's Jeffrey Smith, has discovered that orlistat, commonly prescribed as an anti-obesity drug orlistat, marketed as XenicalT, has a positive side-effect: it inhibits cancer growth. Smith made this discovery using an activity-based proteomics screening technique developed in...

  • A pharmacologic approach to obesity. Lucas, Charles P.; Segal, Karen R.; Hauptman, Jonathan // Contemporary OB/GYN;Jun2000, Vol. 45 Issue 6, p18 

    Evaluates the effectiveness of orlistat for the treatment of obesity. Gender-specific effects of obesity; Effect of orlistat on weight loss; Side effects of orlistat. INSET: Fighting obesity.

  • Topiramate withdrawal.  // Reactions Weekly;6/2/2007, Issue 1154, p22 

    The article presents a case report of an obese man who experienced rebound weight gain following topiramate withdrawal. The man had a body mass index of 32 and a history of multiple dietary treatments followed by weight gain and an unsuccessful orlistat treatment. The man stopped further...

  • New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy. Jinhwa Lee; Kwang-Seop Song; Jahyo Kang; Suk Ho Lee; Junwon Lee // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p564 

    The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe,...

  • Anti-obesity drug use before professional treatment in Taiwan. Tsan-Hon Liou; Chih-Hsing Wu; Hsu-Chen Chien; Wen-Yuan Lin; Wei-Jei Lee; Pesus Chou // Asia Pacific Journal of Clinical Nutrition;Sep2007, Vol. 16 Issue 3, p580 

    Between July 2004 and June 2005, a cross-sectional study was performed to determine the prevalence and patterns of anti-obesity medicine use among subjects seeking obesity treatment in Taiwan. Eighteen obesity outpatient clinics were selected via a random stratified sampling method and 1,060...

  • Obesity drug endorsed by NICE. Wise, Jacqui // BMJ: British Medical Journal (International Edition);03/17/2001, Vol. 322 Issue 7287, p637 

    Reports on the possible availability of the anti-obesity drug orlistat (Xenical) throughout England and Wales on the National Health Service. Decision made by the National Institute for Clinical Excellence (NICE); Guidelines for prescribing orlistat, as one part of the management of obesity;...

  • WEIGHT WATCHER. Springen, Karen // Newsweek;2/6/2006, Vol. 147 Issue 6, p70 

    This article discusses the pros and cons of taking the weight loss drug orlistat, a medication which is marketed by Roche and is sold under the name of Xenical. Orlistat is prescribed by doctors as a weight loss drug and is typically recommended only for those patients suffering from...

  • Review of the pharmacologic arsenal for the war on obesity. Derbyshire, Mary Beth; Shek, Allen; Szkotak, Jonathan // Formulary;Apr2013, Vol. 48 Issue 4, p136 

    Obesity has become a highly prevalent chronic condition that is associated with significant morbidity and mortality. Studies have demonstrated that even as little as 5% to 10% of weight loss is associated with an improvement in cardiovascular risk factors and a reduction in the incidence of type...

  • Orlistat: A Viewpoint by F. Xavier Pi-Sunyer. Pi-Sunyer, F.X. // Drugs;Aug1998, Vol. 56 Issue 2, p250 

    Offers views on the anti-obesity drug orlistat. Mechanism of actio; Toxicity; Effectiveness.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics